Market Newsdesk

-AtlasClearing Remains Compliant with Regulatory Net Capital Requirements as Correspondent Clearing and Onboarding Continue-

-Common Stock Expected to Be Quoted on the OTC Market Under “ATCH” During Appeal-

TAMPA, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (“AtlasClear” or the “Company”), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced that on November 10, 2026, it was notified by NYSE American LLC (the “Exchange”) that the Exchange’s staff has suspended trading in the Company’s common stock, effective immediately, and has determined to commence proceedings to delist the common stock. The Exchange cited Section 1003(f)(v) of the NYSE American Company Guide, based on the low selling price of the common stock.

Key Takeaways

• AtlasClearing’s clearing operations continue in the ordinary course, and AtlasClearing remains compliant with its regulatory net capital requirements.
• The Exchange’s determination is based on the low selling price of the common stock, not on the Company’s operations or regulatory capital.
• AtlasClearing has signed eight correspondent broker-dealer agreements, and onboarding continues.
• The Company intends to appeal. During the appeal process, the common stock is expected to be quoted on the OTC market under the symbol “ATCH.”
• Shareholders continue to own their shares; the suspension does not change the number of shares held or shareholders’ percentage ownership.

The Company intends to appeal the staff’s determination by requesting a hearing before a Listing Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange, as permitted under Section 1203 of the NYSE American Company Guide. During the appeal process, the common stock will remain suspended from trading on the NYSE American and is expected to be quoted on the OTC market. The common stock remains listed on the NYSE American while the appeal is pending. The Exchange has stated that it will apply to the Securities and Exchange Commission to delist the common stock only upon completion of all applicable procedures, including any appeal by the Company. The Company currently intends to seek to effect a reverse stock split as one tool to support its appeal and continued listing. A reverse stock split would not, by itself, change shareholders’ percentage ownership of the Company.

The Exchange’s determination is based solely on the low selling price of the common stock. It does not relate to AtlasClearing’s regulatory capital compliance, the Company’s financial condition or the status of its correspondent clearing operations.

“Our underlying business remains operational, and our strategic priorities have not changed,” said John Schaible, Executive Chairman of AtlasClear Holdings. “We intend to pursue the appeal process and seek to restore trading on the NYSE American, while continuing to execute on our correspondent clearing strategy. AtlasClearing remains compliant with its regulatory capital requirements, and we believe the progress we are making in expanding our clearing platform is what will ultimately define the business.”

“Our correspondent clearing operations continue in the ordinary course, and our team remains focused on bringing additional firms onto the platform,” said Craig Ridenhour, President of AtlasClear Holdings and Chairman of AtlasClearing, Inc. “We have invested in the infrastructure, regulatory capabilities and personnel needed to support these relationships, and that work continues. On the operating side, our focus is on converting signed correspondent agreements into active clearing relationships and building a stronger, more diversified revenue base.”

Clearing Operations and Growth Strategy Continue

AtlasClear’s wholly owned subsidiary, AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.) (“AtlasClearing”), continues to operate its regulated clearing business and remains compliant with applicable net capital requirements. AtlasClearing has signed eight correspondent broker-dealer agreements, and the Company remains focused on expanding its correspondent clearing relationships, onboarding signed broker-dealer clients and developing its integrated financial infrastructure platform.

The Company continues to pursue its strategy of providing clearing and financial infrastructure services to smaller broker-dealers and financial institutions. Management remains focused on translating its growing correspondent network into active clearing activity, recurring revenue opportunities and long-term operating growth.

AtlasClear’s fiscal 2026 revenue increased 85% to $20.1 million, before material contributions from its newly signed correspondents, and cash more than doubled to $15.4 million without the use of an at-the-market offering or equity line.

Trading of Common Stock

The Company’s common stock remains issued and outstanding. During the appeal process, the Company expects its common stock to be quoted on the OTC market operated by OTC Markets Group under the symbol “ATCH.” The Company intends to continue to file reports with the Securities and Exchange Commission and to provide regular updates to shareholders, and holders’ ownership, voting rights and economic interests are unchanged. There can be no assurance that an active trading market will develop on the OTC market or that the appeal will be successful such that trading in the common stock will resume on the NYSE American.

The Company will file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing the Exchange’s notice.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, its pending acquisition of Ark Financial Services, Inc., and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear Holdings seeks to deliver a vertically integrated suite of investment banking, brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company’s appeal of the Exchange’s determination, a potential reverse stock split, the quotation of its common stock on an over-the-counter market, the continuation of its business operations, the onboarding of correspondent broker-dealers and the Company’s growth strategy. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the outcome of any review of the Exchange’s determination; the delisting of the common stock and its effect on liquidity, the market price and the Company’s ability to raise capital; the effect of the suspension or delisting on the Company’s agreements, financing arrangements and pending transactions, including the pending acquisitions of Ark Financial Services, Inc. and Commercial Bancorp of Wyoming; delays in onboarding correspondent broker-dealers; and the other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and subsequent filings. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Company Contact

AtlasClear Holdings, Inc.
Email: [email protected]

Investor Relations Contact

Jeff Ramson, CEO
PCG Advisory, Inc.
Email: [email protected]

SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) —
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO).

With this latest grant, Immutep now holds five United States patents within this patent family. The portfolio has expanded progressively through a series of patents granted in December 2020, March 2021, June 2023, July 2026 and, most recently, this latest patent.

The claims of the new patent build on the protection provided by the four previously granted patents and are directed to combined preparations and pharmaceutical compositions comprising eftilagimod alfa (“efti”) and a PD-1 pathway inhibitor. Specifically, the claims encompass combinations with BMS-936559, durvalumab, atezolizumab and avelumab. The expiry date of the patent is 23 March 2038 (including 806 days of patent term adjustment).

The patent grant provides additional protection for the use of efti in combination with PD-1 pathway inhibitors, a key class of immunotherapies used in modern cancer treatment, further expanding Immutep’s patent portfolio covering efti-based combination therapies. Immutep has also filed a continuation application to pursue additional embodiments of the invention.

Marc Voigt, CEO of Immutep, said: “We are pleased to receive this latest US patent grant, which further strengthens the intellectual property protection surrounding efti. As we pursue our focused development strategy for efti, a good patent portfolio remains an important strategic asset, supporting future development and partnering opportunities. We believe in the potential of this unique biomolecule and that carefully selected clinical settings could provide meaningful opportunities for continued evaluation and value creation.”

About Eftilagimod Alfa (Efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; [email protected]

U.S. Investors/Media:

Matthew Beck, astr partners
+1 (917) 415 1750; [email protected]

SAN JUAN CAPISTRANO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), which invests in facilities that provide skilled nursing and senior living services, physical, occupational and speech therapies, and other rehabilitative and healthcare services, today announced that 101 of its independently operating affiliates have been recognized and included in the listing of the 2027 Best Nursing Homes by U.S. News & World Report.

Since 2009, U.S. News’ annual Best Nursing Homes analysis has served as an independent, data-driven guide for families navigating short-term rehabilitation or comprehensive long-term care choices. Each Ensign-affiliated facility on the list earned a High Performing rating – the highest distinction awarded by U.S. News – reflecting outstanding quality in Short-Term Rehabilitation, Long-Term Care, or both.

Recognizing only 18% of evaluated facilities across the nation for 2027, U.S. News’ Best Nursing Homes designation reflects a high standard of care. This designation is reserved only for skilled nursing facilities that satisfy U.S. News’ rigorous, proprietary assessment criteria demonstrating a consistent and superior commitment to quality and resident-centered care.

“I am deeply grateful to the caregivers and leaders who earned this important recognition,” said Barry Port, Ensign’s Chief Executive Officer. “Being named among the nation’s best nursing homes is evidence of their dedication to clinical excellence and reflects the exceptional care they deliver to residents every day.”

“Earning a High Performing rating from U.S. News reflects a continuous, facility-wide commitment to superior resident care,” said Jordan Derk, Ph.D., senior care researcher at U.S. News. “When families see this distinction, they can feel confident that this skilled nursing facility has demonstrated exceptional outcomes.”

For the 2027 edition, U.S. News evaluated more than 14,600 nursing homes in the United States, assessing key indicators such as hospital readmission rates, staffing levels, health inspection results and other indicators of quality. The 2027 U.S. News Best Nursing Homes ratings rely on a comprehensive evaluation framework, assessing 17 distinct quality measures across both Short-Term Rehabilitation and Long-Term Care categories to deliver a thorough analysis of overall nursing home quality.

For patients and families evaluating their options, choosing a skilled nursing facility recognized by U.S. News with a Best Nursing Home designation provides a trusted starting point to discuss in consultation with their healthcare provider.

For more information, visit USNews.com and use #BestNursingHomes on Facebook, Instagram, LinkedIn, Threads, TikTok and X.

About U.S. News & World Report
U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, insurance, personal finance, travel, automobiles, real estate, careers and consumer products and services.

About Ensign:
The Ensign Group, Inc.’s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 418 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information:
[email protected] (949) 487-9500

IRVINE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Phoenix Energy One, LLC (NYSE American, PHXE.P) (“Phoenix Energy” or the “Company”), an energy company focused on oil and gas exploration and production across key U.S. basins, today reported its financial and operating results for the third quarter ended September 30, 2026, and raised its full-year 2026 outlook, on Form 10-Q with the U.S. Securities and Exchange Commission.

Q3 2026 Highlights

• Generated total revenues of $460.4 million, net loss of $1.4 million, EBITDA of $148.6 million, and Adjusted EBITDA of $207.8 million in Q3 2026, as compared to total revenues of $189.0 million, net income of $8.5 million, EBITDA of $92.6 million, and Adjusted EBITDA of $88.9 million in Q3 2025;
• Cash flow provided by operating activities was $489.0 million for the nine months ended September 30, 2026, as compared to $204.7 million for the nine months ended September 30, 2025;
• Achieved the Company’s highest quarterly gross crude oil production to date with 4.4 million barrels of crude oil produced in Q3 2026, the highest monthly gross crude oil production to date with 1.5 million barrels of crude oil produced in August 2026, and the highest daily gross crude oil production to date with 52,479 barrels of crude oil produced in September 2026;
• In August 2026, the Company was the eighth largest producer of crude oil in North Dakota;
• Released rigs on 22 Bakken production wells, of which 19 were three-mile lateral wells, two were four-mile lateral wells, and one was a switchback well, which had an average lateral length of approximately 16,144 feet;
• Completed hydraulic fracturing on 15 wells, consisting of 11 four-mile lateral wells and 4 three-mile lateral wells, and placed 5 wells into production, including the Company’s first four-mile lateral switchback wells, which were the first such wells drilled in Montana;
• Received the first permits ever issued for five-mile lateral wells in the Williston Basin; and
• Produced approximately 14.2 million barrels of water and injected approximately 14.2 million barrels through the Company’s saltwater disposal wells, with approximately 99.5% of total produced water volumes handled internally through the Company’s operated facilities.

2026 Outlook

Based on results for the nine months ended September 30, 2026, and its expectations for the remainder of the year, the Company is updating its full-year 2026 outlook. The updated outlook below supersedes the outlook previously provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026.

		As filed in Q3 2026 Form 10-Q												As filed in 2025 Form 10-K
		Year Ending December 31, 2026												Year Ending December 31, 2026
(dollars in thousands)				Lower Range						Upper Range						Lower Range					Upper Range
Revenue		$		1,610,000		(1)		$		1,780,000		(1)		$		1,190,000			$		1,490,000
Total operating expenses		$		1,060,000				$		1,120,000				$		965,000			$		1,030,000
Net income (loss)		$		(40,000	)	(2)		$		120,000		(2)		$		(40,000	)		$		65,000
EBITDA		$		525,000		(3)		$		695,000		(3)		$		475,000			$		605,000
Adjusted EBITDA		$		725,000		(3)		$		850,000		(3)		$	N/A				$	N/A
Total outstanding debt		$		2,090,000		(4)		$		2,230,000		(4)		$		1,900,000			$		2,150,000
Production:
Crude oil (Bbls)				13,100,000						13,700,000						12,500,000					13,600,000
Natural gas (Mcf)				17,500,000		(5)				18,200,000		(5)				14,900,000					16,300,000
NGL (Bbls)				1,550,000						1,640,000						475,000					520,000
Total (Boe) (6:1)				17,566,667						18,373,333						15,458,333					16,836,667
Average daily production (Boe/d) (6:1)				48,128						50,338						42,352					46,128

1. Based on an average benchmark commodity price of $88.39/Bbl for crude oil and $2.27/MMBtu for natural gas. Oil prices have been significantly volatile during 2026. Oil prices rose sharply in the first half of the year following the onset of the conflict in the Middle East involving Iran, Israel, the United States, and other countries in the region, reaching a high of $112.95 per Bbl on April 7, 2026. During the third quarter, oil prices ranged from a low of $69.60 per Bbl on July 6, 2026 to a high of $107.02 per Bbl on September 15, 2026, driven in part by renewed disruptions to shipping in the region.
2. Net income projections are subject to significant variability due to the accounting treatment of our derivative instruments. We use derivative instruments to manage exposure to commodity price volatility. These instruments are accounted for at fair value under GAAP, with changes in fair value recognized in earnings each reporting period. As a result, reported net income may be significantly impacted by unrealized gains or losses resulting from changes in forward commodity price curves related to future production periods, including 2026, 2027, 2028, and 2029. Our hedge positions currently result in derivative losses when crude oil prices rise. A substantial increase in forward crude oil prices, particularly late in the fourth quarter of 2026, would increase these losses before the higher prices are reflected in revenue, and could result in a net loss for the fourth quarter, which is reflected in the lower end of the net income (loss) range. Because these adjustments reflect changes in market expectations for future commodity prices rather than current operational performance, reported net income (loss) may fluctuate materially from period to period and may not be indicative of the Company’s underlying operating performance. Accordingly, deviations from projected net income (loss), EBITDA, or Adjusted EBITDA due primarily to non-cash mark-to-market adjustments on derivative instruments may occur even if operational performance remains consistent with expectations, and the Company may elect not to update previously issued net income (loss), EBITDA, or Adjusted EBITDA guidance when such deviations occur.
3. EBITDA and Adjusted EBITDA are non-GAAP financial measures. See “Non-GAAP Financial Measures” below for a reconciliation to net income (loss), the most directly comparable financial measure under GAAP. Assumes interest expense ranging between $240.0 million and $250.0 million and depreciation, depletion, and amortization expense ranging between $315.0 million and $335.0 million during the year ending December 31, 2026. We have not provided a full reconciliation of our forward outlook for EBITDA in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. We are unable to predict with reasonable certainty the specific amount and timing of certain items required to provide a full reconciliation, in particular due to the impact that commodity prices can have on our derivative positions.
4. Assumes repayment of an aggregate of $148.0 million of debt outstanding as of December 31, 2025 and that matures prior to December 31, 2026, no prepayments of debt that is not maturing prior to December 31, 2026, and the issuance of between $708.1 million and $848.1 million of new debt during the year ending December 31, 2026.
5. Revenue from natural gas has not historically represented a significant portion of our total revenues. We anticipate this trend to continue and, as a result, we currently estimate 5,350,000 Mcf to 5,650,000 Mcf of natural gas volumes (of the production range presented above) will be sold and recognized as revenues for the year ending December 31, 2026.

Q3 2026 Quarter and Year to Date Financial Results

		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)			2026				2025				2026				2025
Total revenues		$	460,385			$	189,021			$	1,164,916			$	468,602
Net income (loss)			(1,404	)			8,488				(35,538	)			32,785
EBITDA(1)			148,590				92,551				359,409				256,512
Adjusted EBITDA(1)			207,773				88,906				519,252				242,399
(1) EBITDA and Adjusted EBITDA are non-GAAP measures. See “Non-GAAP Financial Measures” below for a reconciliation to net income (loss), the most directly comparable financial measure under GAAP.

Net loss for the three months ended September 30, 2026 was $1.4 million, as compared to net income of $8.5 million for the same period in 2025. The year-over-year change was primarily due to an $89.9 million increase in loss on derivatives as a result of net cash settlements on matured contracts and unfavorable changes in the mark-to-market value of the Company’s outstanding commodity derivatives, a $43.2 million increase in depreciation, depletion, and amortization expense primarily due to increases in the Company’s depletable cost bases, a $38.2 million increase in cost of sales primarily associated with higher production volumes from the Company’s oil and gas operating activities, and a $22.8 million increase in interest expense, net, primarily due to increased interest costs associated with the Company’s term loan facility and the issuance of additional interest-bearing securities. These unfavorable variances were partially offset by a $144.5 million increase in product sales generated from the Company’s operated properties driven by additional wells placed into service, and a $35.6 million increase in mineral and royalty revenues primarily driven by a 35.1% increase in the average realized price for crude oil from $62.97/Bbl for the three months ended September 30, 2025 to $85.09/Bbl for the three months ended September 30, 2026, and a 51.0% and 30.3% increase in production volumes for crude oil and natural gas, respectively, from the Company’s acquisitions of mineral and non-operated working interests.

Net loss for the nine months ended September 30, 2026 was $35.5 million, as compared to net income of $32.8 million for the same period in 2025. The year-over-year change was primarily due to a $277.9 million increase in loss on derivatives as a result of net cash settlements on matured contracts and unfavorable changes in the mark-to-market value of the Company’s outstanding commodity derivatives, a $109.9 million increase in depreciation, depletion, and amortization expense primarily due to increases in the Company’s depletable cost bases, an $83.6 million increase in cost of sales primarily associated with higher production volumes from the Company’s oil and gas operating activities, and a $60.7 million increase in interest expense, net, primarily due to increased interest costs associated with the Company’s term loan facility and the issuance of additional interest-bearing securities. These unfavorable variances were partially offset by a $386.5 million increase in product sales generated from the Company’s operated properties driven by additional wells placed into service, and a $58.6 million increase in mineral and royalty revenues primarily driven by a 26.7% increase in the average realized price for crude oil from $65.36/Bbl for the nine months ended September 30, 2025 to $82.78/Bbl for the nine months ended September 30, 2026, and a 30.9% and 31.4% increase in production volumes for crude oil and natural gas, respectively, from the Company’s acquisitions of mineral and non-operated working interests.

Q3 2026 Quarter and Year to Date Operational Results

			Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Net oil-equivalent sales volumes (BOE)			4,229,601				2,550,211				11,248,689				6,477,302
Average daily sales volumes (BOE/d) (6:1)			45,974				27,720				41,204				23,726

• Average daily sales volume was 45,974 net Boe per day for the three months ended September 30, 2026, as compared to 27,720 net Boe per day for the same period in 2025, an increase of 65.9%. Average daily sales volume was 41,204 net Boe per day for the nine months ended September 30, 2026, as compared to 23,726 net Boe per day for the same period in 2025, an increase of 73.7%; and
• During the nine months ended September 30, 2026, the E&P operators of the Company’s properties, including PhoenixOp, drilled 445 gross and 53.6 net productive development wells on the acreage underlying the Company’s mineral and royalty interests, and the Company had 150 producing wells in service as of September 30, 2026, as compared to 78 producing wells in service as of September 30, 2025.

From Adam Ferrari, Chief Executive Officer

“We produced more oil this quarter than at any point in Phoenix Energy’s history. Revenue grew nearly two and a half times to $460 million, and we nearly doubled the number of producing wells in service. Our bottom line reflects hedging losses as oil prices rose, a natural result of the dynamics of today’s market. Our business remains as strong as ever.”

Phoenix Energy previously announced that it will hold a public earnings call on Wednesday, November 11, 2026 at 1:30 PM PT to review these results. Participants may access the webcast and presentation materials on the Company’s investor-relations website at https://phoenixenergy.com/investors/.

The Form 10-Q filing can be viewed in its entirety via the U.S. Securities and Exchange Commission’s EDGAR database or on Phoenix Energy’s website at https://phoenixenergy.com/investors/.

About Phoenix Energy

Phoenix Energy One, LLC, doing business as Phoenix Energy, is an energy company formed in 2019. The company is focused on oil and gas exploration and production across key U.S. basins, with a primary footprint in the Williston Basin of North Dakota and Montana. Phoenix Energy operates under a differentiated three-pronged strategy of direct drilling, royalty acquisition, and non-operated working interests. For more information on Phoenix Energy, please visit our website at https://phoenixenergy.com/.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, which are statements regarding all matters that are not historical facts. Forward-looking statements may be identified using words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. Forward-looking statements in this release include, but are not limited to, our expectations regarding our financial position and financial and operating performance, including our outlook and guidance for 2026, our assumptions underlying such guidance, and the impact of commodity price volatility on our derivative instruments, as well as our expectations regarding improved operational efficiencies.

Forward-looking statements are based on Phoenix Energy’s beliefs, assumptions, and expectations, taking into account currently known market conditions and other factors. Phoenix Energy’s ability to predict results or the actual effect of future events, actions, plans, or strategies is inherently uncertain and involves certain risks and uncertainties, many of which are beyond its control. Phoenix Energy’s actual results and performance could differ materially from those set forth or anticipated in its forward-looking statements. You are cautioned that the forward-looking statements contained in this press release are not guarantees of future performance, and we cannot assure you that such statements will be realized or that the forward-looking events and circumstances will occur. All forward-looking statements in this press release are made only as of the date of this press release, based on information available to Phoenix Energy as of the date of this press release, and you are cautioned not to place undue reliance on forward-looking statements considering the risks and uncertainties associated with them.

Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. Management believes that these factors include but are not limited to the risk factors the Company has identified in its filings with the U.S. Securities and Exchange Commission, including in the section of its Annual Report on Form 10-K for the year ended December 31, 2025, under the heading “Risk Factors,” and subsequent Quarterly Reports on Form 10-Q. Risk factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in such forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures” that are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, the Company presents “EBITDA” and “Adjusted EBITDA” as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. The Company believes these measures can assist investors in comparing the Company’s operating performance across reporting periods on a consistent basis by excluding items that it does not believe are indicative of its core operating performance. Management believes these non-GAAP measures are useful in highlighting trends in the Company’s operating performance, while other measures can differ significantly depending on long term strategic decisions regarding capital structure, capital investments, etc. Management uses these non-GAAP measures to supplement GAAP measures of performance in the evaluation of the effectiveness of the Company’s business strategies and to make budgeting decisions. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide. However, these measures should not be considered as alternatives to net income (loss) as a measure of financial performance or cash provided by operating activities as a measure of liquidity, or any other performance measure derived in accordance with GAAP. The presentation of these measures has limitations as analytical tools and should not be considered in isolation, or as a substitute for the Company’s results as reported under GAAP.

PHOENIX ENERGY ONE, LLC AND SUBSIDIARIES

Reconciliation of Non-GAAP Measures

The following table shows a reconciliation of EBITDA and Adjusted EBITDA to net income (loss), the most comparable GAAP measure, for the periods presented:

		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)		2026				2025				2026				2025
Net income (loss)		$	(1,404	)		$	8,488			$	(35,538	)		$	32,785
Interest income			(324	)			(303	)			(712	)			(1,355	)
Interest expense, net			61,575				38,816				172,414				111,690
Depreciation, depletion, and amortization			88,743				45,550				223,245				113,392
EBITDA			148,590				92,551				359,409				256,512
Unrealized (gain) loss on derivatives			59,183				(3,645	)			159,843				(14,113	)
Adjusted EBITDA		$	207,773			$	88,906			$	519,252			$	242,399

Contact

Company: Phoenix Energy One, LLC

Email: [email protected]

Address: 18575 Jamboree Road, Suite 830, Irvine, CA 92612

Phone: 949-416-5037

• First survival data from EFTISARC-NEO, released in CTOS 2026 Abstract, demonstrate encouraging preliminary long-term outcomes in patients with resectable soft tissue sarcoma (STS).
• With a median follow-up of 19.1 months, 12-month disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates were 81.1%, 94.1% and 86.2%, respectively, in 38 evaluable patients.
• Investigators conclude that efti plus KEYTRUDA
  
  ^®
  
  (pembrolizumab) and radiotherapy as neoadjuvant therapy showed promising preliminary long-term outcomes warranting registrationally relevant trials in patients with STS.
• Further and new analyses will be presented in a poster discussion session
  on 19 November 2026 and will be the subject of a further announcement by the Company.

SYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) —
Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and clinicopathological correlates from EFTISARC-NEO, the investigator-initiated Phase II trial of eftilagimod alfa (efti) plus KEYTRUDA^® (pembrolizumab) and radiotherapy as neoadjuvant treatment for resectable soft tissue sarcoma (STS). Further detail and analyses will be presented in a poster discussion session on 19 November 2026 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, being held from 18–21 November 2026 in Seoul, South Korea.

As reported in October 2025, EFTISARC-NEO has met its primary endpoint, with a median tumour hyalinisation/fibrosis of 51.5% in 38 evaluable patients, well above the pre-specified target of 35% and approximately 15% historically observed with radiotherapy alone.¹ Health-related quality of life data presented at the ESMO Congress 2026 in October showed no significant deterioration during treatment and a statistically significant improvement following surgery. The U.S. Food and Drug Administration granted Orphan Drug Designation to efti for the treatment of STS in April 2026. The survival outcomes reported here are secondary endpoints of the trial.

With a median follow-up of 19.1 months, the 12-month disease-free survival (DFS), local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) rates were 81.1%, 94.1% and 86.2%, respectively, in 38 evaluable patients (data cut-off 30 April 2026). No differences in DFS were observed across tumour grade, stage or histological subtype.

The investigators concluded that efti plus pembrolizumab on top of standard radiotherapy as neoadjuvant therapy showed promising preliminary long-term outcomes warranting registrationally relevant trials in patients with STS. The investigators reported that high infiltration by tumour-infiltrating lymphocytes (TIL) and tumour hyalinisation/fibrosis after therapy may be associated with better DFS but that longer follow-up is necessary.

Follow-up for DFS and overall survival is ongoing.

For further details see the Events section of Immutep’s website. The poster with updated data will be made available on the Posters & Publications page of Immutep’s website at www.immutep.com following its presentation at the meeting.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa in combination with KEYTRUDA^® (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti. The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.

Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.

Disclaimer

This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

¹ Schaefer IM, Hornick JL, Barysauskas CM, Raut CP, Patel SA, Royce TJ, Fletcher CDM, Baldini EH. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):375-383.

Australian Investors/Media:

Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; [email protected]

US Investors/Media:

Matthew Beck, astr partners
+1 (917) 415-1750; [email protected]

HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) — Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that it will issue its third quarter 2026 earnings release on Monday, November 23, 2026 after the market close and host a conference call to discuss its financial and operating results on Tuesday, November 24, 2026 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time).

Interested parties in the United States and Canada may participate toll-free by dialing (833) 816-1385. International parties may participate by dialing (412) 317-0478. Participants should ask to be joined to the “Epsilon Energy Third Quarter 2026 Earnings Conference Call.”

A webcast can be viewed at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZeZjRfnX. A webcast replay will be available on the Company’s website (www.epsilonenergyltd.com) following the call.

About Epsilon

Epsilon Energy Ltd. is a North American onshore natural gas and oil production and gathering company with assets across the Appalachian, Powder River, Permian, and Western Canadian Sedimentary basins.

Contact Information:

281-670-0002

Jason Stabell
Chief Executive Officer
[email protected]

Andrew Williamson
Chief Financial Officer
[email protected]

SEOUL, South Korea, Nov. 10, 2026 (GLOBE NEWSWIRE) — DoubleU Games Co., Ltd. (KRX: 192080) (“DoubleU Games”) and DoubleDown Interactive Co., Ltd. (Nasdaq: DDI) (“DoubleDown”) today announced that DoubleU Games commenced its all-cash tender offer to acquire all outstanding American Depositary Shares (“ADSs”, each representing one-twentieth (1/20) of one common share) of DoubleDown not already owned by DoubleU Games or its affiliates for US$16.25 per ADS, net to the seller in cash, without interest and less any applicable withholding taxes, pursuant to the Tender Offer and Post-Offer Cooperation Agreement, dated as of November 9, 2026, between DoubleU Games and DoubleDown (the “Agreement”). The price and other terms were negotiated by a special committee of the DoubleDown board of directors composed solely of independent and disinterested directors (the “Special Committee”), with the advice of its independent legal and financial advisors. The Special Committee unanimously (i) determined that the Agreement and the transactions contemplated thereby (the “Transactions”), including the offer, are advisable, fair to, and in the best interests of, DoubleDown and its shareholders, including holders other than DoubleU Games, its affiliates and the directors and officers of DoubleU Games and DoubleDown (the “Unaffiliated Holders”), and (ii) recommended that DoubleDown’s board of directors (the “DDI Board”) approve the Agreement and the Transactions. Following that recommendation by the Special Committee, and after considering the fairness opinion of the Special Committee’s financial advisor and in consultation with its advisors, the DDI Board unanimously (i) determined that the Agreement and the Transactions are advisable, fair to, and in the best interests of, DoubleDown and its shareholders, including the Unaffiliated Holders, (ii) approved the Agreement and the Transactions, and (iii) recommended that DoubleDown’s Unaffiliated Holders accept the offer and tender their ADSs pursuant to the offer.

The tender offer is subject to customary conditions, including (i) a minimum tender condition that DoubleU Games would own at least 95% of DoubleDown’s outstanding common shares immediately following the acceptance for payment of all ADSs validly tendered and not validly withdrawn in the offer, as determined by reference to the certificate of the tender agent (the “Minimum Tender Condition”), provided that, if DoubleU Games reasonably determines that the Minimum Tender Condition is not reasonably expected to be satisfied, DoubleU Games may, after consulting in good faith with the Special Committee and with the prior written consent of DoubleDown (given by the DDI Board following the recommendation of the Special Committee), which consent shall not be unreasonably withheld, conditioned or delayed, reduce but not waive, the Minimum Tender Condition to not less than 90%; (ii) a non-waivable “majority-of-the-minority” condition that more than 50% of the ADSs held by the Unaffiliated Holders be validly tendered and not validly withdrawn; and (iii) the recommendation of the DDI Board to the Unaffiliated Holders to accept the offer and tender their ADSs pursuant to the offer having been made and not withdrawn or adversely modified (which condition DoubleU Games may waive in its sole discretion). In the event that the offer is completed, DoubleU Games has agreed to acquire the remaining common shares (including common shares represented by ADSs) not acquired in the offer through a second-step transaction under the Korean Commercial Act for the same price per ADS that it pays pursuant to the offer.   

The Special Committee received a fairness opinion from Kroll, LLC, operating through its Duff & Phelps Opinions Practice, its independent financial advisor, in connection with the tender offer. The tender offer is not subject to any financing conditions. DoubleU Games is obligated to pay the cash required pursuant to the tender offer if all conditions of the offer are satisfied. DoubleU Games expects to fund the offer and the second-step transaction with cash on hand and financing from a bridge loan facility of up to KRW300 billion provided by the lenders named therein, for which Korea Investment & Securities Co., Ltd. is acting as mandated lead arranger, facility agent and security agent. Completion of the offer remains subject to the conditions described above; there can be no assurance that the offer will be completed.

Paul Hastings LLP and Kim & Chang are serving as U.S. and Korean legal counsel, respectively, to DoubleU Games. Roth Capital Partners, LLC is acting as dealer manager, Georgeson LLC is acting as information agent and Citibank, N.A. is acting as tender agent for the offer. Kroll, LLC is serving as financial advisor to the Special Committee, and Ropes & Gray LLP and Lawfirm Goodplan are serving as U.S. and Korean legal counsel, respectively, to the Special Committee. Greenberg Traurig, LLP and Bae, Kim & Lee LLC are serving as U.S. and Korean legal counsel, respectively, to DoubleDown.

Additional Information and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of DoubleDown. This communication is not a substitute for the tender offer materials that DoubleU Games and DoubleDown have filed with the U.S.
Securities and Exchange Commission (the “SEC”). DoubleU Games has filed a Tender Offer Statement on Schedule TO (including an Offer to Purchase, a related Letter of Transmittal and other offer documents), DoubleU Games and DoubleDown have jointly filed a Rule 13e-3 Transaction Statement on Schedule 13E-3 (which may be combined with the Schedule TO), and DoubleDown has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer.

HOLDERS OF ADSs ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS), THE SCHEDULE 13E-3 AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING A TENDER OF THEIR ADSs. These materials are available free of charge on the SEC’s website at www.sec.gov. The tender offer materials may also be obtained free of charge from Georgeson LLC, the information agent for the offer, toll free at +1 (888) 745-7950 (or +1 (516) 454-5409 from outside the U.S. and Canada) or by email at [email protected]. Free copies of the documents filed by DoubleDown may also be obtained by contacting DoubleDown at [email protected] or by visiting DoubleDown’s website at https://doubledowninteractive.com.

Forward-Looking Statements

This communication contains forward-looking statements, including statements regarding the tender offer, the second-step transaction, the expected timing of the Transactions, the anticipated delisting of the ADSs and the termination of DoubleDown’s reporting obligations. Forward-looking statements are based on current expectations and are subject to risks and uncertainties, including uncertainties as to the timing of the tender offer; how many ADS holders will tender their ADSs; the possibility that the minimum tender condition (which may be reduced by DoubleU Games, with the prior written consent of DoubleDown, such consent not to be unreasonably withheld, conditioned or delayed, to not lower than 90%, but not waived) or the non-waivable majority-of-the-minority condition will not be satisfied; the possibility that the second-step transaction will not be completed or will be delayed, including where approval of DoubleU Games’ shareholders is required; the effects of the Transactions on relationships with employees, players, platform providers and business partners; litigation relating to the Transactions; transaction costs; fluctuations in the Korean won to U.S. dollar exchange rate; the effect of the announcement on the trading price of the ADSs; and the other risks described in DoubleDown’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and its other filings with the SEC, and in DoubleU Games’ public disclosures in Korea. Actual results may differ materially. Neither DoubleU Games nor DoubleDown undertakes any obligation to update any forward-looking statement, except as required by law.

About DoubleU Games

DoubleU Games Co., Ltd. (KRX: 192080), headquartered in Seoul, is the controlling shareholder of DoubleDown Interactive Co., Ltd., owning approximately 67.05% of its outstanding common shares.

About DoubleDown Interactive

DoubleDown Interactive Co., Ltd. is a leading developer and publisher of digital games on mobile and web-based platforms. We are the creators of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. DoubleDown’s flagship social casino title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. Through its subsidiary WHOW Games GmbH, headquartered in Hamburg, Germany, DoubleDown offers exciting social casino experiences to European players. In addition, DoubleDown’s subsidiary, SuprNation, operates three real-money iGaming sites in Western Europe.

Contacts:

DoubleU Games Investor Relations — Tel +82-2-501-7216 — Email [email protected] |

DoubleDown Investor Relations —

Joe Sigrist, Chief Financial Officer — Tel +1 (206) 773-2266 — Email [email protected]

Joseph Jaffoni, Christin Armacost, JCIR — Tel +1 (212) 835-8500 — Email [email protected]

Georgeson LLC, Information Agent —

Toll Free +1 (888) 745-7950 (or +1 (516) 454-5409 from outside the U.S. and Canada)

Email [email protected]

New York, Nov. 10, 2026 (GLOBE NEWSWIRE) — Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of $1.2 million for its client JIADE LIMITED (NASDAQ: JDZG) (the “Company” or “JIADE”), a provider of one-stop comprehensive education support services for adult education institutions through its subsidiaries in the People’s Republic of China.

Under the terms of the securities purchase agreement, the Company has agreed to sell to an institutional investor 6,666,666 Class A Ordinary Shares of the Company (or pre-funded warrants in lieu thereof), at a purchase price of $0.18 per share in the Offering.

The aggregate gross proceeds to the Company were approximately $1.2 million, before deducting placement agent fees and other offering expenses payable by the Company.

Univest Securities, LLC acted as the sole placement agent.

The registered direct offering was made pursuant to a shelf registration statement on Form F-3 (File No. 333-292574) previously filed by the Company and declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 13, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering were filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Univest Securities, LLC at [email protected], or by calling +1 (212) 343-8888.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct offering, together with the accompanying base prospectus, can be obtained at the SEC’s website at www.sec.gov.

About Univest Securities, LLC

Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally, including brokerage and execution services, sales and trading, market making, investment banking and advisory, and wealth management. It strives to provide clients with value-added service and focuses on building long-term relationships with its clients. As a prominent name on Wall Street, Univest has successfully raised over $1.8 billion in capital for issuers across the globe since 2019 and has completed approximately 100 transactions spanning a wide array of investment banking services in various industries, including technology, life sciences, industrial, consumer goods, etc. For more information, please visit: www.univest.us.

About JIADE LIMITED

JIADE LIMITED (Nasdaq: JDZG) provides one-stop comprehensive education support services for adult education institutions in China. Through its subsidiaries, the Company offers software-driven and service-based solutions centered around the Kebiao Technology Educational Administration Platform (“KB Platform”), which streamlines enrollment, student management, learning progress tracking, grade inquiry, and graduation management. JIADE also provides auxiliary services such as pre-enrollment guidance, exam training, application support, tutoring, and exam administration. As of June 30, 2026, the Company has collectively provided one-stop comprehensive education supporting services to over 17 adult education institutions and had collectively provided education supporting services to approximately 115,114 students, newly provided safety technology training services for approximately 21,834 individuals and online course services for approximately 138,473 individuals.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at

www.sec.gov

. Univest Securities, LLC and the Company undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Univest Securities, LLC

Edric Guo

Chief Executive Officer

75 Rockefeller Plaza, Suite 25A
New York, NY 10019
Phone: (212) 343-8888
Email: [email protected]